期刊文献+

药学服务应用于乳腺癌患者辅助内分泌治疗中的效果分析 被引量:1

Analysis on the Effect of Pharmaceutical Service on Adjuvant Endocrine Therapy in Patients with Breast Cancer
暂未订购
导出
摘要 目的探讨药学服务应用于乳腺癌患者辅助内分泌治疗中的效果。方法选取2017年1-9月34例未实施临床药学服务患者为对照组,选取2017年10月-2018年6月36例实施临床药学服务患者为观察组。比较两组患者的不良反应发生率、特定指标复查率和用药依从性。结果观察组的不良反应发生率低于对照组(30.56%vs70.59%,χ^2=11.209,P=0.001),妇检复查率高于对照组(100%vs53.33%,χ^2=11.165,P=0.001),骨密度检查复查率高于对照组(100%vs57.89%,χ^2=9.203,P=0.002),血常规和肝功能检查复查率高于对照组(100%vs61.76%,χ^2=16.904,P=0.001),用药依从性高于对照组(100%vs73.53%,χ^2=10.935,P=0.001)。结论临床药师参与乳腺癌辅助内分泌治疗,有助于减少用药物后的不良反应率,提高特定指标复查率,改善用药的依从性。 OBJECTIVE To explore the effect of pharmaceutical services in adjuvant endocrine therapy for breast cancer patients. METHODS From January 2017 to September 2017,34 patients with endocrine therapy for breast cancer were selected as the control group(no clinical pharmacy service). 36 patients from October 2017 to June 2018 were the observation group(implement clinical pharmacy services).The incidence of adverse reactions,the rate of review of specific indicators and medication adherence were compared. RESULTS The incidence of adverse reactions in the observation group was significantly lower than the control group(30.56%vs70.59%,χ^2=11.209,P=0.001).The gynecological examination rate of the observation group was higher than the control group(100%vs53.33%,χ^2=11.165,P=0.001), and the bone mineral density examination review rate was higher than the control group(100%vs57.89%,χ^2=9.203, P=0.002),the blood routine and liver function test review rate was higher than the control group(100%vs61.76%,χ^2=16.904,P=0.001).The medication compliance of the observation group was higher than the control group(100%vs73.53%,χ^2=10.935,P=0.001).CONCLUSION Clinical pharmacists involved in breast cancer adjuvant endocrine therapy could help reduce the adverse reaction rate after use,improve the review rate of specific indicators,improve medication compliance,and promote the rational use of endocrine therapy after breast cancer surgery.
作者 李锦 张迎 LI Jin;ZHANG-Ying(Pengpu Xincun Street Community Health Service Center,Jing’an District,Shanghai,200435,China)
出处 《中国初级卫生保健》 2019年第7期79-80,83,共3页 Chinese Primary Health Care
关键词 药学服务 乳腺癌 内分泌治疗 pharmaceutical service beast cancer endocrine therapy
  • 相关文献

参考文献8

二级参考文献73

  • 1李金锋,徐光炜.乳腺癌的早期诊断与治疗[J].中华全科医师杂志,2005,4(6):336-338. 被引量:29
  • 2杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:281
  • 3Parkin DM, Bray F, Feflay J, et al. Global cancer statistics ,2002 [J]. CA Cancer J Clin,2005,55(2) :74-108.
  • 4中华人民共和国卫生部.中国卫生部卫生统计年鉴[EB/OL]. (2012-09-14) [2013-12-12]. http://www, moh. gov. en/ publicflles/business/htmlfiles/ zwgkzt/ ptjnj/ year2010/ index2010. html.
  • 5McCowan C,Shearer J,Donnan PT,et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer[J]. Br J Cancer,2008,99( 11 ) :1763-1768.
  • 6Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients [ J ]. J Clin Oncol,2010,28 (27) :4120-4128.
  • 7Nekhlyudov L, Li L, Ross-Degnan D, et al. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer [ J ]. Breast Cancer Res Treat,2011,130 (2) :681-689.
  • 8Weaver KE, Camacho F, Hwang W, et al. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low - income women [ J ]. Am J Clin Oneol, 2013,36(2) :181-187.
  • 9Huiart L, Dell' Aniello S, Suissa S. Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer[ J ]. Br J Cancer,2011,104 (10) : 1558-1563,.
  • 10Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients [ J]. J Clin Oncol, 2010, 28 (27) :4120-4128.

共引文献110

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部